| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
|
N Engl J Med
|
2012
|
10.07
|
|
2
|
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
|
J Clin Oncol
|
2011
|
3.83
|
|
3
|
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
|
Blood
|
2013
|
2.60
|
|
4
|
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
|
Haematologica
|
2013
|
1.67
|
|
5
|
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
|
Haematologica
|
2015
|
1.32
|
|
6
|
Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
|
Curr Med Chem
|
2012
|
1.16
|
|
7
|
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
|
Haematologica
|
2015
|
1.10
|
|
8
|
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
|
Haematologica
|
2013
|
1.02
|
|
9
|
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
|
Int J Gen Med
|
2014
|
0.98
|
|
10
|
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
|
Haematologica
|
2013
|
0.97
|
|
11
|
Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.
|
Leukemia
|
2013
|
0.95
|
|
12
|
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
|
Ther Clin Risk Manag
|
2012
|
0.93
|
|
13
|
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
|
Onco Targets Ther
|
2016
|
0.88
|
|
14
|
The evolving treatment paradigm in myelofibrosis.
|
Leuk Lymphoma
|
2012
|
0.84
|
|
15
|
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
|
Exp Hematol Oncol
|
2015
|
0.84
|
|
16
|
Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.
|
Cancer Med
|
2013
|
0.81
|
|
17
|
Definition and management of ruxolitinib treatment failure in myelofibrosis.
|
Blood Cancer J
|
2014
|
0.80
|
|
18
|
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.
|
BioDrugs
|
2013
|
0.78
|
|
19
|
Emerging drugs for myelofibrosis.
|
Expert Opin Emerg Drugs
|
2012
|
0.77
|
|
20
|
Efficacy of ruxolitinib for myelofibrosis.
|
Expert Opin Pharmacother
|
2014
|
0.77
|